All
Updated Analysis of Prostate Cancer Trials Continue to Demonstrate Benefit with Xtandi
March 24th 2015Two studies investigating Xtandi in men with early-stage metastatic castration-resistant prostate cancer (mCRPC) further confirmed the overall survival (OS) and progression-free survival (PFS) benefit of the agent over placebo, according to two recent studies.
Evolving Role of Lymph Node Biopsies After Neoadjuvant Therapy for Breast Cancer
March 24th 2015Surgical oncologist Kelly K. Hunt, of MD Anderson Cancer Center, discusses how breast cancer interventions have progressed in the adjuvant and neoadjuvant setting and the role of sentinel lymph node dissection in the neoadjuvant setting.
The Evolving Challenges of Targeting PI3K in Breast Cancer
March 13th 2015Josh D. Lauring, of Johns Hopkins Medicine, is interested in identifying the genetic changes that drive breast cancer growth in order to determine novel therapeutic targets for drug development and ultimately improve outcomes for patients with breast cancer.
Higher Risk of Thyroid Cancer Among Those With Breast Cancer History
March 11th 2015According to a recent analysis of a large national database, patients with a history of breast cancer have a higher risk of developing thyroid cancer than the general population, particularly if they receive adjuvant radiation therapy.